Palmitoylethanolamide (PEA)

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that reduces neuroinflammation and peripheral pain, showing efficacy in chronic pain conditions such as diabetic neuropathy, fibromyalgia, and osteoarthritis. It is well-tolerated with no known drug interactions.

painanti inflammatoryneuroprotectionmoodsleep

Evidence last reviewed: 20 Apr 2026

Buy ← Back

Your fit analysis

Generic — sign in for a personalised view

Generic

In your favour

On the other hand

Evidence

4 records

4 recordsBest grade:High

Biomarkers

TNF-αIL-6

PEA has shown significant efficacy in reducing chronic pain, particularly in adults with conditions like fibromyalgia and diabetic neuropathy. While some studies indicate benefits for menstrual pain and metabolic syndrome, the overall evidence is still developing, and further research is needed to confirm its effectiveness across various populations.

Chronic pain reduction

Adults with chronic pain · Meta-analysis

High

PEA was associated with significantly greater pain reduction compared to inactive control conditions.

Dose: 600 mg

Citation: Gabrielsson et al. (2016). Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Journal of the American Chemical Society.

Proinflammatory marker reduction

Unvaccinated adults with COVID-19 · RCT

Moderate

PEA reduced proinflammatory markers in adults recently diagnosed with COVID-19.

Dose: 600 mg

Citation: Fessler et al. (2022). Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial. Annual Review of Pharmacology and Toxicology.

Pain reduction in metabolic syndrome

Metabolic syndrome patients · RCT

Low

Preliminary results suggest PEA may aid in pain management for metabolic syndrome patients.

Dose: 600 mgForm: Co-micronized with Rutin

Citation: Cornali et al. (2025). The Effects of a Food Supplement, Based on Co-Micronized Palmitoylethanolamide (PEA)-Rutin and Hydroxytyrosol, in Metabolic Syndrome Patients: Preliminary Results. Journal of Clinical Pharmacology.

Study focused on metabolic syndrome.

Acute menstrual pain reduction

Adults with menstrual pain · RCT

Moderate

PEA significantly reduced acute menstrual pain scores compared to placebo.

Dose: 300 mgDuration: Single doseTiming: At pain onset

Study focused on menstrual pain relief.

Stacks containing Palmitoylethanolamide (PEA)

Explore all →

No public stacks include this supplement yet.

Community Insights

Forms & usage▾

How to take it

Take 300-600 mg daily, preferably with meals.

Micronized

Enhanced absorption and bioavailability.

Co-micronized with Rutin

Combined with rutin for synergistic effects.

Levagen+

A branded form with improved solubility.

My notes▾